Please login to the form below
drug licensing
This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.
First oral antiviral drug for COVID-19 reviewed by Health Canada
An oral antiviral drug is seen by many as an essential part of an effective medical toolkit against COVID-19. ... Merck has also signed voluntary licensing agreements with five Indian generic drug manufacturers to expand access to molnupiravir, and
Latest news
-
J&J exits $1.6bn blood cancer drug licensing deal with argenx
Johnson &Johnson (J&J) has pulled out of a $1.6bn licensing deal with Dutch biotech company argenx for the CD70-targeting antibody cusatuzumab. ... In December 2018, J&J and argenx signed a deal centred on cusatuzumab, to develop the drug for the
-
Merck enters agreement with Hanmi for investigational NASH drug
NGM313 is an antibody targeting the beta-Klotho/FGFR1c receptor complex that could represent a new a completely new drug class for NASH and diabetes. ... The drug works by activating FGFR1c signalling, a pathway that appears to have a key role in
-
Moderna and GSK advance coronavirus vaccine candidates
The drug was originally being developed as a treatment for the infectious diseases Ebola and Marbug virus. ... However, despite successfully copying and manufacturing the drug, BrightGene has said it will not launch the drug until it has received
-
China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
However, Gilead which holds all patents around the development and production of the drug – including for its development as a treatment for coronavirus. ... Although BrightGene has said it has successfully developed and manufactured copies of the drug,
-
EU, US biotechs merge to create fibrosis, cancer player
the new one has different ideas on how to pursue studies with this drug”. ... The US biotech had put the LOXL2 drug out for tender as a licensing candidate, and has also already hived off another research programme headed by autotaxin inhibitor PAT-409
More from news
Approximately 2 fully matching, plus 63 partially matching documents found.
Latest Intelligence
-
Alzheimer’s disease: the search for a cure
Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... The most successful projects will validate strong genetic targets and will include licensing opportunities for leading drug target
-
The changing nature of approvals – what does the future hold?
into drug development costs and approval trends based on data and analyses from multiple proprietary data sets. ... Based on CMR International data, since 2015 we have seen the number of drug commercialisation/licensing deals continue to gradually
-
‘Flexible working’: fashionable buzzword or fundamental business operation?
Externally, there are the usual issues: downward pressure on hourly rates, reduced client budgets, environmental pressures on new drug development and licensing/reimbursement.
-
Charting a course for expansion
a key licensing agreement and the not inconsequential matter of a management reshuffle. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug
-
Pharma deals during January 2013
Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.
More from intelligence
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Ipsen bolsters leadership team
Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
COUCH Health recruits Rosemary Lakeru as Director of Patient Recruitment, Feasibility and Diversity
Better patient diversity is critical for clinical trials, in order to develop the right drugs for the right patients, and to support successful drug approvals and effective marketing and communication campaigns. ... Drug licensing and regulatory bodies
-
Drivers of 2014′s Soaring Drug Approvals
The FDA &EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future launch teams and some of the key areas of focus which could make or break a
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
